Where does Zynerba Pharmaceuticals, Inc. rank among US patent assignees?

According to USPTO PatentsView (2015–2025 granted utility patents), Zynerba Pharmaceuticals, Inc. ranks #22,090 of 49,997 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.

How many patents does Zynerba Pharmaceuticals, Inc. hold?

Zynerba Pharmaceuticals, Inc. holds 13 US utility patents granted between 2015 and 2023, spanning 5 technology areas.

What is Zynerba Pharmaceuticals, Inc.'s Innovation Score?

Zynerba Pharmaceuticals, Inc. has an Innovation Score of 26.0 out of 100 (19th percentile of the corpus). This composite metric weighs portfolio volume (40%), grant velocity (20%), technology breadth (25%), and claim depth (15%).

What technology areas does Zynerba Pharmaceuticals, Inc. focus on?

Zynerba Pharmaceuticals, Inc.'s top technology area is A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations) with 12 patents, ranking #1,593 of 6,058 assignees active in that subclass. Grants appear in 5 CPC subclasses total.

Is Zynerba Pharmaceuticals, Inc.'s patent grant rate increasing or decreasing?

Zynerba Pharmaceuticals, Inc.'s recent grant velocity is -14% compared to the prior five-year period (grant years, not application filing dates). Grant activity has slowed relative to earlier years.

What does claim depth mean for Zynerba Pharmaceuticals, Inc.'s patents?

Zynerba Pharmaceuticals, Inc.'s patents average 9.5 claims each. This is an aggregate descriptive count from the grant record; it does not establish claim scope, legal strength, enforceability, or design-around risk.

How is the Zynerba Pharmaceuticals, Inc. patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

USPTO 2015–2025 USPTO PatentsView US Corporation

Zynerba Pharmaceuticals, Inc.

USPTO PatentsView assignee record - 13 granted patents across 5 technology areas, recorded in grant years 2015–2023. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations).

Compiled by PlainPatent · May 15, 2026

RSS updates for this company

Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, Zynerba ranks #22,090 of 49,997 tracked US assignees by granted-patent volume, with 13 patents across 5 technology areas.

#22,090
of 49,997 US assignees by volume: 19th percentile
by Innovation Score (26.0/100): 9.5
avg claims per patent: -14%
grant velocity, last 5 yrs

USPTO PatentsView assignee plate

Corpus R22090 · US Corporation #22,090 · 13 grants

GRANTS-MICRO · MID-PACK · PHOTO-FINISH · CPC-NARROW · INNOV-THIN · CLAIMS-PAR · TYPE-USCORP · VEL-DOWN · BOOK-FULL

GRANTS-MICRO 13 grants
MID-PACK #22,090/49,997
PHOTO-FINISH Zambon S P A
CPC-NARROW A61P · 5 areas
INNOV-THIN 26.0/100
CLAIMS-PAR 9.5 claims/avg
TYPE-USCORP US Corporation
VEL-DOWN -14% vel
BOOK-FULL 10/10 fields

Nearest grant-volume peer: Zambon S.P.A. (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

How Zynerba’s 26.0 Innovation Score adds up

The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.

Volume 9.1 pts (35%) Velocity 3.3 pts (13%) Breadth 7.9 pts (30%) Claim depth 5.7 pts (22%)

Qualcomm Incorporated · highest

85
Zynerba Pharmaceutic… · this assignee

26
3D Lighting… · lowest

7

What this shows Zynerba's Innovation Score is 26.0/100 (19th percentile of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Does more volume mean deeper claims for Zynerba?

Each dot is one of Zynerba’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). Zynerba’s own 9.5 claims/patent is at or below the 13.9 median for these volume peers. Volume here does not track with deeper claims; several lower-volume peers claim more thoroughly per patent.

Zynerba vs its 8 nearest volume peers: granted patents vs average claims per patent. Source: USPTO PatentsView.

Where Zynerba's grants concentrate

Zynerba Pharmaceuticals, Inc. is a focused PatentsView assignee: 5 CPC subclasses with 92.3% of grants classified under A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations). Peak complete grant year is 2019 (3 grants) versus a trough of 1 in 2015. By volume, Zynerba sits between Zhejiang Sanhua Co., Ltd and Zhejiang Huakang Pharmaceutical Co., Ltd..

Zynerba's three-year grant acceleration

Zynerba Pharmaceuticals, Inc. shows 3 grants in 2022–2024 against only 6 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.

Zhejiang Sanhua

13
Zhuhai Hengqin Su…

13
Zoll Respicardia

13
ZTE Microelectron…

13
ZYP Coatings

13
Zambon S P A

13
Zetta

13
Zhejiang Huakang…

13
Zynerba Pharmaceu… ◀

13

What this shows Zynerba holds 13 patents at rank #22,077, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near Zynerba

By rank, the assignees closest to #22,077 in granted patent volume.

Leaders in A61P (Specific Therapeutic Activity OF Chemical Compounds OR Me…)

Other assignees with the most granted patents in Zynerba's primary technology class.

Zynerba's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

26 19th percentile higher than 19% of 49,997 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2015–2023

Grants by year

Teal-shaded recent years (2020–present) versus the 2015–2019 baseline. Full figures in the table below.

View data table

Zynerba Pharmaceuticals, Inc. patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2015	1	7.7%
2017	2	15.4%
2018	1	7.7%
2019	3	23.1%
2020	3	23.1%
2022	2	15.4%
2023	1	7.7%

Which technologies does Zynerba Pharmaceuticals, Inc. patent most?

A61P - Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations 12

A61K - Preparations FOR Medical, Dental OR Toiletry Purposes 12

C07D - Heterocyclic Compounds 3

C07F - Acyclic, Carbocyclic OR Heterocyclic Compounds Containing Elements Other Than Carbon, Hydrogen, Halogen, Oxygen, Nitrogen, Sulfur, Selenium OR Tellurium 3

C07C - Acyclic OR Carbocyclic Compounds 1

Top 5 of 5 technology areas

More on this record

Data Source

USPTO PatentsView, US granted patents 2015–2025

View all rankings → How is Innovation Score calculated?

What to do with this data

Zynerba Pharmaceuticals, Inc.'s patent record in context - here's where to go next.

Zynerba Pharmaceuticals, Inc.'s lead technology class is A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations), 92.3% of its portfolio - see every assignee active in that class. Explore A61P
Ranked #22,090 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
Compare Zynerba Pharmaceuticals, Inc. against Zhejiang Sanhua Co., Ltd, an assignee filing at a similar volume. Compare portfolios
Innovation Score of 26.0/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled by PlainPatent, US Patent Intelligence Editorial Process · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.